New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib

References

• SiegelRLMillerKDJemalACancer statisticsCA Cancer J Clin201565152925559415
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature2007448715356156617625570
   PubMed Web of Science ®Google Scholar
• IwaharaTFujimotoJWenDMolecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous systemOncogene19971444394499053841
   PubMed Web of Science ®Google Scholar
• ChoiYLTakeuchiKSodaMIdentification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancerCancer Res200868134971497618593892
   PubMed Web of Science ®Google Scholar
• TakeuchiKChoiYLTogashiYKIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancerClin Cancer Res20091593143314919383809
   PubMed Web of Science ®Google Scholar
• SodaMTakadaSTakeuchiKA mouse model for EML4-ALK-positive lung cancerProc Natl Acad Sci U S A200810550198931989719064915
   PubMed Web of Science ®Google Scholar
• OkamotoINakagawaKEchinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspectsCancer Sci201210381391139622568572
   PubMed Web of Science ®Google Scholar
• SasakiTRodigSJChirieacLRJannePAThe biology and treatment of EML4-ALK non-small cell lung cancerEur J Cancer201046101773178020418096
   PubMed Web of Science ®Google Scholar
• ScagliottiGStahelRARosellRThatcherNSoriaJCALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug developmentEur J Cancer201248796197322397764
   PubMed Web of Science ®Google Scholar
• GainorJFVargheseAMOuS-HIALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancerClin Cancer Res201319154273428123729361
   PubMed Web of Science ®Google Scholar
• ZhangXZhangSYangXFusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expressionMol Cancer2010918820624322
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• RothschildSIGautschiOCrizotinib in the treatment of non-small-cell lung cancerClin Lung Cancer201314547348023790969
   PubMed Web of Science ®Google Scholar
• ShawATKimDWNakagawaKPhase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) (PROFILE 1007)Ann Oncol201223Suppl 9LBA1_PR
   Google Scholar
• SolomonBJMokTKimD-WFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology – Non-Small Cell Lung CancerFort Washington, PANCCN2015
   Google Scholar
• ChoiYLSodaMYamashitaYEML4-ALK mutations in lung cancer that confer resistance to ALK inhibitorsN Engl J Med2010363181734173920979473
   PubMed Web of Science ®Google Scholar
• SasakiTKoivunenJOginoAA novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitorsCancer Res201171186051606021791641
   PubMed Web of Science ®Google Scholar
• HeuckmannJMHölzelMSosMLALK mutations conferring differential resistance to structurally diverse ALK inhibitorsClin Cancer Res201117237394740121948233
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res20121851472148222235099
   PubMed Web of Science ®Google Scholar
• KatayamaRShawATKhanTMMechanisms of acquired crizotinib resistance in ALK-rearranged lung cancersSci Transl Med20124120120r a17
   Web of Science ®Google Scholar
• MarsiljeTHPeiWChenBSynthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamJ Med Chem201356145675569023742252
   PubMed Web of Science ®Google Scholar
• FribouletLLiNKatayamaRThe ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerCancer Discov20144666267324675041
   PubMed Web of Science ®Google Scholar
• NiZZhangT-CComputationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancerJ Mol Model201521717526084268
   PubMed Web of Science ®Google Scholar
• CooperMRChimHChanHDurandCCeritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancerAnn Pharmacother201549110711225258420
   PubMed Web of Science ®Google Scholar
• KatayamaRLovlyCMShawATTherapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicineClin Cancer Res201521102227223525979929
   PubMed Web of Science ®Google Scholar
• KatayamaRFribouletLKoikeSTwo novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibClin Cancer Res201420225686569625228534
   PubMed Web of Science ®Google Scholar
• SequistLVGettingerSSenzerNNActivity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancerJ Clin Oncol201028334953496020940188
   PubMed Web of Science ®Google Scholar
• Zykadia^® (ceritinib) capsules [prescribing information]Novartis PharmaSwitzerland2015
   Google Scholar
• ShawATKimD-WMehraRCeritinib in ALK-rearranged non-small-cell lung cancerN Engl J Med2014370131189119724670165
   PubMed Web of Science ®Google Scholar
• FelipEKimD-WMehraREfficacy and safety of ceritinib in patients (pts) with advanced anaplastic lymphoma kinase (ALK-) rearranged (ALK+) non-small cell lung cancer (NSCLC): an update of ASCEND-1Ann Oncol201425Suppl 41295P
   Google Scholar
• MokTSpigelDFelipEASCEND-2: a single-arm, open-label, multicenter phase 2 study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ)J Clin Oncol201533Suppl abstr 8059
   Google Scholar
• FelipEOrlovSParkKASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC)J Clin Oncol201533Suppl abstr 8060
   Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer20094522824719097774
   PubMed Web of Science ®Google Scholar
• RangachariDYamaguchiNVanderLaanPABrain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancersLung Cancer201588110811125682925
   PubMed Web of Science ®Google Scholar
• CostaDBShawATOuS-HIClinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastasesJ Clin Oncol201533171881188825624436
   PubMed Web of Science ®Google Scholar
• ShawAMehraRTanDSWBM-32Ceritinib (LDK378) for treatment of patients with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases (BM) in the ASCEND-1 trialNeuro Onco201416Suppl 939
   Web of Science ®Google Scholar
• Chugai’s ALK Inhibitor “Alecensa®” Trial Stopped Early for Benefit. [press release]Tokyo, Japan Business Wire; 2016 [February 10]. Available from: http://www.businesswire.com/news/home/20160210005605/en/Chugais-ALK-Inhibitor-Alecensa%C2%AE-Trial-Stopped-EarlyAccessed April 28, 2016
   Google Scholar
• SakamotoHTsukaguchiTHiroshimaSCH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutantCancer Cell201119567969021575866
   PubMed Web of Science ®Google Scholar